Aerobic Training and Cardiopulmonary Responses In Heart Failure

NCT07128784 | Completed

• 1 other identifier: TABED 2-25-1203
• Study Type: observational
• Target: 21
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this observational study is to learn about the short-term effects of aerobic exercise in heart failure patients who were given exercise prescription with cardiopulmonary exercise stres test acocording to aerobic capacity . The main question it aims to answer is: Does aerobic exercise increase aerobic capacity and quality of life Participants already taking aerobic capacity as part of their regular medical care for Heart failure will asses with cardiopulmonary exercise test and clinical questionaries about quality of life and depression-anxiety level before and after aerobic exercise treatment .

Conditions

Heart Failure; Cardiopulmonary Exercise Test; Aerobic Capacity; Aerobic Exercise

Keywords

cardiopulmonary exercise test; aerobic capacity; aerobic exercise; heart failure

Outcome Measures

Primary Outcomes (4)

• cardiopulmonary exercise test results

  Cardiovascular responses: VO2 max value (ml/kg/dk)

  6 weeks

• cardiopulmonary exercise test results

  Cardiovascular responses: heart rate (bpm, beats/min)

  6 weeks

• cardiopulmonary exercise test results

  gas exchange response: VE/VCO2: EQCO2: Ventilatory equivalent for carbon dioxide minute ventilation while the produced CO₂ is removed,

  6 weeks

• cardiovascular exercise test result: Gas exchange parameters:

  PETCO₂ (partial end-tidal carbon dioxide), kilopascal

  6 weeks

Secondary Outcomes (2)

• Short Form (36) Health Scale

  6 weeks

• Hospital Anxiety and Depression Scale

  6 weeks

Study Arms (1)

aerobic exercise

Other: Aerobic exercise

Interventions

Aerobic exercise OTHER

continuous, moderate intencity aerobic exercise, 3 days a week, 30 minutes per day, 150/min per week for a total of 6 weeks

aerobic exercise

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

18-75 age of years , male and female , diagnosed with heart failure with reduced EF

You may qualify if:

• Age 18-75,
• Diagnosed with compensated HF,
• BMI 18-30 kg/m²,
• LVEF \< 0.4,
• NYHA 2-3,
• Clinical symptoms have been stable for at least 2 weeks, and the dose of angiotensin-converting enzyme inhibitor/angiotensin receptor antagonist/angiotensin receptor inhibitor, beta-blocker, aldosterone inhibitor, and other drugs has been stable for at least 2 weeks.

You may not qualify if:

• History of a heart implant device within the last 6 weeks or a heart implant device or heart transplant plan within the next 12 months,
• Acute coronary syndrome within the last 6 weeks, severe valvular heart disease, congenital heart disease, severe hypertrophic obstructive cardiomyopathy, acute myocarditis/pericarditis, intracardiac thrombosis, primary pulmonary hypertension,
• Uncontrolled hypertension (systolic blood pressure \>200 mmHg and/or diastolic blood pressure \>110 mmHg),
• Severe arrhythmias such as ventricular tachycardia, frequent multisource premature ventricular beats, high atrioventricular block, and significant QT interval prolongation during exercise testing,
• Progressive dyspnea or
• Loss of exercise endurance at rest within the last 3-5 days under low-intensity exercise load (\<2 MET) who have suffered myocardial ischemia,
• Patients with cognitive impairment.

Sponsors & Collaborators

• Ankara City Hospital Bilkent: lead

Study Sites (1)

Ankara City Hospital

Ankara, Çankaya, 06800, Turkey (Türkiye)

Location

Related Publications (2)

• Lelonek M. Heart failure with preserved ejection fraction after the PARAGON-HF trial results: current knowledge and future directions. Kardiol Pol. 2020 Dec 23;78(12):1199-1205. doi: 10.33963/KP.15639. Epub 2020 Oct 6.

  PMID: 33021355 BACKGROUND

• Conrad N, Judge A, Tran J, Mohseni H, Hedgecott D, Crespillo AP, Allison M, Hemingway H, Cleland JG, McMurray JJV, Rahimi K. Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. Lancet. 2018 Feb 10;391(10120):572-580. doi: 10.1016/S0140-6736(17)32520-5. Epub 2017 Nov 21.

  PMID: 29174292 BACKGROUND

MeSH Terms

Conditions

Heart Failure

Interventions

Exercise

Condition Hierarchy (Ancestors)

Heart Diseases; Cardiovascular Diseases

Intervention Hierarchy (Ancestors)

Motor Activity; Movement; Musculoskeletal Physiological Phenomena; Musculoskeletal and Neural Physiological Phenomena

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 12, 2025
• First Posted: August 19, 2025
• Study Start: April 1, 2025
• Primary Completion: June 15, 2025
• Study Completion: June 20, 2025
• Last Updated: August 19, 2025

Record last verified: 2025-08

Data Sharing

• IPD Sharing: Will not share

Locations

TU (1)